160 related articles for article (PubMed ID: 23451142)
21. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
22. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer.
Chen X; Xu Y; Liao X; Liao R; Zhang L; Niu K; Li T; Li D; Chen Z; Duan Y; Sun J
Tumour Biol; 2016 Sep; 37(9):11927-11936. PubMed ID: 27075472
[TBL] [Abstract][Full Text] [Related]
23. Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1).
Rui W; Bing F; Hai-Zhu S; Wei D; Long-Bang C
J Cell Mol Med; 2010 Jan; 14(1-2):206-14. PubMed ID: 19900214
[TBL] [Abstract][Full Text] [Related]
24. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
25. A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.
Tan EH; Ramlau R; Pluzanska A; Kuo HP; Reck M; Milanowski J; Au JS; Felip E; Yang PC; Damyanov D; Orlov S; Akimov M; Delmar P; Essioux L; Hillenbach C; Klughammer B; McLoughlin P; Baselga J
Ann Oncol; 2010 Feb; 21(2):217-222. PubMed ID: 20110292
[TBL] [Abstract][Full Text] [Related]
26. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
27. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin-based chemotherapy in elderly patients with advanced stage (IIIB and IV) non-small cell lung cancer patients.
Ozkaya S; Findik S; Atici AG; Dirica A
Neoplasma; 2011; 58(4):348-51. PubMed ID: 21520993
[TBL] [Abstract][Full Text] [Related]
29. Thrombocytosis and immunohistochemical expression of connexin 43 at diagnosis predict survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Du G; Yang Y; Zhang Y; Sun T; Liu W; Wang Y; Li J; Zhang H
Cancer Chemother Pharmacol; 2013 Apr; 71(4):893-904. PubMed ID: 23355038
[TBL] [Abstract][Full Text] [Related]
30. Non-surgical therapy for patients with advanced non-small cell lung cancer.
Liao M
Respirology; 1998 Sep; 3(3):151-7. PubMed ID: 9767613
[TBL] [Abstract][Full Text] [Related]
31. DNA methylation of hMLH1 correlates with the clinical response to cisplatin after a surgical resection in Non-small cell lung cancer.
Wu F; Lu M; Qu L; Li DQ; Hu CH
Int J Clin Exp Pathol; 2015; 8(5):5457-63. PubMed ID: 26191250
[TBL] [Abstract][Full Text] [Related]
32. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.
Bai H; Wang Z; Chen K; Zhao J; Lee JJ; Wang S; Zhou Q; Zhuo M; Mao L; An T; Duan J; Yang L; Wu M; Liang Z; Wang Y; Kang X; Wang J
J Clin Oncol; 2012 Sep; 30(25):3077-83. PubMed ID: 22826274
[TBL] [Abstract][Full Text] [Related]
33. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536
[TBL] [Abstract][Full Text] [Related]
34. Blood-based gene expression signatures in non-small cell lung cancer.
Zander T; Hofmann A; Staratschek-Jox A; Classen S; Debey-Pascher S; Maisel D; Ansén S; Hahn M; Beyer M; Thomas RK; Gathof B; Mauch C; Delank KS; Engel-Riedel W; Wichmann HE; Stoelben E; Schultze JL; Wolf J
Clin Cancer Res; 2011 May; 17(10):3360-7. PubMed ID: 21558400
[TBL] [Abstract][Full Text] [Related]
35. Significance of glucocorticoid receptor expression in patients with non-small cell lung cancer treated with pemetrexed-based chemotherapy.
Zhao XM; Zhao J; Wu XH; Luo ZG; Wang HJ; Yu H; Chang JH; Wang JL
Cancer Chemother Pharmacol; 2017 Oct; 80(4):851-860. PubMed ID: 28755014
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
37. Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine.
Viñolas N; Provencio M; Reguart N; Cardenal F; Alberola V; Sánchez-Torres JM; Barón FJ; Cobo M; Maestu I; Moreno I; Mesía C; Izquierdo A; Felip E; López-Brea M; Márquez A; Sánchez-Ronco M; Tarón M; Santarpia MC; Rosell R;
Lung Cancer; 2011 Feb; 71(2):191-8. PubMed ID: 20627363
[TBL] [Abstract][Full Text] [Related]
38. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
O'Byrne KJ; Gatzemeier U; Bondarenko I; Barrios C; Eschbach C; Martens UM; Hotko Y; Kortsik C; Paz-Ares L; Pereira JR; von Pawel J; Ramlau R; Roh JK; Yu CT; Stroh C; Celik I; Schueler A; Pirker R
Lancet Oncol; 2011 Aug; 12(8):795-805. PubMed ID: 21782507
[TBL] [Abstract][Full Text] [Related]
39. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy.
Cui EH; Li HJ; Hua F; Wang B; Mao W; Feng XR; Li JY; Wang X
Acta Pharmacol Sin; 2013 Feb; 34(2):309-13. PubMed ID: 22983388
[TBL] [Abstract][Full Text] [Related]
40. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
